WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergence Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY072, our potential first- and best-in-class anti-TL1A agent in de ...

Core Insights - Spyre Therapeutics, Inc. has successfully closed an underwritten public offering of 17,094,594 shares of common stock at a price of $18.50 per share, raising approximately $316.2 million in gross proceeds before expenses [1] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [5]

Group 1: U.S. Stock Market Overview - U.S. stocks experienced a decline, with the Dow Jones index dropping approximately 300 points on Tuesday [1] Group 2: Domino's Pizza, Inc. Performance - Domino's Pizza reported third-quarter earnings per share of $4.08, surpassing the analyst consensus estimate of $3.96 [1] - The company's quarterly sales reached $1.147 billion, reflecting a year-over-year increase of 6.2%, exceeding the expected $1.137 billion [1] - Following the positive financial results, Domino's shares increased by 4.1% to $424.95 on Tuesday [1] Group 3: Notable Stock Gains - Astria Therapeutics, Inc. shares surged 40.6% to $11.91 after BioCryst announced plans to acquire the company [4] - Critical Metals Corp. shares rose 22.9% to $28.62 amid U.S.-China trade tensions and JPMorgan's $1.5 trillion initiative [4] - Trilogy Metals Inc. gained 20.6% to $7.93 [4] - American Resources Corporation jumped 17.5% to $5.85, participating in additional October conferences [4] - Navitas Semiconductor Corporation rose 16.3% to $11.60 after providing a progress update on its power devices [4] - Telefonaktiebolaget LM Ericsson gained 16% to $9.47, reporting third-quarter EPS and sales above estimates [4] - Rocket Pharmaceuticals, Inc. increased by 15.5% to $4.0100 after FDA acceptance of its Biologics License Application resubmission [4] - Orla Mining Ltd. surged 11.2% to $12.74, reporting strong gold production from Musselwhite [4] - Albertsons Companies, Inc. rose 9.7% to $18.58 after better-than-expected second-quarter results and a $750 million share repurchase agreement [4] - Polaris Inc. gained 9.2% to $66.98, announcing the divestment of its majority stake in Indian Motorcycle [4] - Spyre Therapeutics, Inc. rose 11.2% to $21.04, pricing a $275 million public offering of common stock [4]

Core Viewpoint - Spyre Therapeutics, Inc. has announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, aiming to raise approximately $275.0 million in gross proceeds before expenses [1][2]. Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [5]. Offering Details - The public offering is expected to close around October 15, 2025, pending customary closing conditions [2]. - The underwriters have an option to purchase an additional 2,229,729 shares at the public offering price [1]. - Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are the joint book-running managers for the offering [2]. Regulatory Information - A registration statement related to the offering has been filed with the SEC and became effective on March 7, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus [3].

Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced therapies for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [1][3] Group 1: Scientific Developments - The company presented follow-up data from a Phase 1 study of SPY002, an anti-TL1A agent, showing it is well tolerated and supports quarterly or biannual dosing, with efficacy in suppressing free TL1A for up to 24 weeks [2] - New preclinical data indicates that combination therapies (α4β7 + TL1A, α4β7 + IL-23, TL1A + IL-23) demonstrate superior efficacy compared to individual monotherapies in rodent models of colitis, supporting ongoing Phase 2 studies [2] Group 2: Pipeline and Future Directions - Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, aiming to create next-generation treatments for IBD and other immune-mediated diseases [3]

Group 1 - Spyre Therapeutics Inc. (NASDAQ:SYRE) has been recognized as one of the 10 Best Debt Free Small Cap Stocks to Buy Now, indicating significant upside potential for investors [1] - The company has enrolled its first patient in the Phase 2 SKYWAY trial, which targets multiple autoimmune diseases and assesses its lead antibody program in patients unresponsive to standard treatments [2] - As this is Spyre's second Phase 2 program, initial data is expected in 2026, with several proof-of-concept readouts planned over the next two years [3] Group 2 - Spyre Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory bowel disease and is noted for being one of the Best Debt Free Stocks [3]

Group 1 - Spyre Therapeutics (NASDAQ: SYRE) is focused on the clinical development of multiple antibodies aimed at treating inflammatory diseases, with the potential for these antibodies to be best-in-class [1] - The company emphasizes the importance of intelligent trial design and development decisions in maximizing the potential of its antibody candidates [1]

Summary of Spyre Therapeutics Conference Call Company Overview - **Company**: Spyre Therapeutics (NasdaqGS:SYRE) - **Focus**: Addressing unmet needs in autoimmune diseases, particularly Inflammatory Bowel Disease (IBD) and rheumatic diseases through innovative antibody therapies [2][4] Core Points and Arguments IBD Research and Development - **Ongoing Trials**: Two phase 2 trials targeting IBD using optimized antibodies against three key targets: 47, TL1A, and the P19 subunit of IL-23 [2][3] - **Combination Therapy**: The strategy involves co-formulated combinations to block multiple pathways in IBD, aiming for improved efficacy and safety [3][4] - **Market Potential**: The indications targeted by these studies represent a market exceeding $60 billion in annual revenue [4] Efficacy and Safety Insights - **Combination Efficacy**: Historical data from Johnson & Johnson's Vega study indicates that combining therapies can significantly improve clinical remission rates (nearly 50% vs. 25% for monotherapies) [6][10] - **Future Expectations**: Anticipation of incremental efficacy in refractory populations, with a focus on maintaining safety profiles [10][12] Competitive Landscape - **Bispecific vs. Co-formulated Antibodies**: Spyre has opted for co-formulations over bispecifics due to lower immunogenicity risks and better target engagement [18][20][21] - **Small Molecule Development**: The company views small molecules as less likely to match the efficacy of biologics, particularly in combination therapies [22][23] TL1A Antibodies - **Phase 1 Results**: Two TL1A antibodies (SPY-002 and SPY-072) are advancing to phase 2 trials based on favorable product profiles [24] - **Safety Monitoring**: Concerns regarding chest tightness in phase 1 were deemed non-critical, with normal vital signs observed [25] Study Design and Objectives - **Skyline Study**: A platform trial designed to evaluate multiple therapies and combinations, aiming for proof of concept and optimal product identification [27][31] - **Dosing Strategy**: Initial intravenous (IV) dosing followed by subcutaneous maintenance to ensure blinding and assess efficacy [32][34] Future Outlook - **Data Readouts**: Expectation of multiple readouts in 2026 and 2027, with a focus on both IBD and rheumatic diseases [41][46] - **Financial Position**: The company has $527 million in cash, sufficient to fund operations into the second half of 2028, supporting ongoing and future studies [46] Additional Important Insights - **Market Dynamics**: The company is positioned to capture significant value in the autoimmune market, with a focus on combination therapies to address complex disease mechanisms [45] - **Strategic Partnerships**: While the company aims to advance its therapies independently, it acknowledges potential interest from strategic partners [44] This summary encapsulates the key points discussed during the conference call, highlighting Spyre Therapeutics' strategic focus, ongoing research, and market potential in the autoimmune disease sector.

Core Insights - SPY072 is a potential first- and best-in-class anti-TL1A antibody designed for the treatment of rheumatic diseases, with a dosing regimen of quarterly or twice-yearly subcutaneous injections [1][2][5] - The SKYWAY study is currently evaluating SPY072 in patients with moderate-to-severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with proof-of-concept data expected in 2026 [1][3] - The company anticipates delivering nine proof-of-concept readouts from the SKYWAY and SKYLINE trials between 2026 and 2027, targeting a market with over $60 billion in annual revenue [4] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [6] - The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, aiming to address significant unmet medical needs in rheumatic diseases [6] Clinical Development - The SKYWAY Phase 2 trial is a randomized, placebo-controlled study assessing SPY072 in patients with inadequate response to existing therapies, with topline data expected in 2026 [3][5] - Interim data from a Phase 1 trial indicated that SPY072 was well tolerated and demonstrated prolonged pharmacokinetics, suggesting its potential efficacy in treating rheumatic diseases [5]

Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced antibody engineering and therapeutic combinations for treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases [1][3] Group 1: Company Overview - Spyre Therapeutics aims to create next-generation products for IBD and other immune-mediated diseases through best-in-class antibody engineering, dose optimization, and rational therapeutic combinations [3] - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 [3] Group 2: Upcoming Events - Management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 10:00 a.m. ET [2] - Live audio webcasts and replays of the events will be available on the Spyre investor events website [2]